Tag: liso-cel

Find relevant news articles from other European projects, below:


Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:


Dr. Solomon on the Effects of Liso-Cel in Prior Anti-CD19 Therapy–Treated B-NHL

Scott R. Solomon, MD, discusses the effects of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell non-Hodgkin lymphoma who were previously treated with CD19-directed therapies.

Visit website
NEWS medical 2

FDA approves cell-based gene therapy to treat adults with relapsed or refractory...

Today, the U.S. Food and Drug Administration approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment.

Visit website

Liso-Cel Responses Not Impacted By Prior Anti-CD19 Therapy in Relapsed/Refractor...

Prior exposure to anti-CD19 therapy did not impact response to the CAR T-cell therapy lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.

Visit website

Liso-Cel BLA for Relapsed/Refractory LBCL Remains Under FDA Review

The biologics license application for the CAR T-cell product lisocabtagene maraleucel in adult patients with relapsed/refractory large B-cell lymphoma following at least 2 previous therapies continues to be under regulatory review by the FDA, and a decision on the application has not yet been reached.

Visit website
Immunotherapy Web Featured Images 45

ASH 2020 | TRANSCEND CLL 04: 18-month follow-up of liso-cel for R/R CLL

Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the findings of a trial (NCT03386513) of IMGN632, a novel antibody-drug conjugate (ADC), in relapsed/refractory (R/R) blastic plasmacytoid dendritic cell neoplasm (BPDCN), a setting with poor outcomes and minimal treatment options.

Visit website